Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 590368-25-5 Chemical Structure| 590368-25-5

Structure of Upamostat
CAS No.: 590368-25-5

Chemical Structure| 590368-25-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Upamostat is an orally active uPA inhibitor, suitable for research on fibrinolysis-related diseases.

Synonyms: WX-671

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Upamostat

CAS No. :590368-25-5
Formula : C32H47N5O6S
M.W : 629.81
SMILES Code : O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(NO)=N)=C3)=O)CC1)OCC
Synonyms :
WX-671
MDL No. :MFCD20526529

Safety of Upamostat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HuCCT1 83 µM 0, 6, 12, and 24 hours To evaluate the effects of Upamostat and Opaganib on cell viability and migration in the cholangiocarcinoma cell line HuCCT1. Results showed that both WX-UK1 and Opaganib individually and in combination led to cell growth regression and reduced migration. Cancers (Basel). 2024 Mar 5;16(5):1050

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Cholangiocarcinoma patient-derived xenograft model (PAX165) Oral gavage 70 mg/kg Upamostat, 50 mg/kg Opaganib Once daily for 6 weeks To evaluate the effects of Upamostat and Opaganib, alone or in combination, on tumor growth in a cholangiocarcinoma xenograft model. Results showed that both Upamostat and Opaganib significantly inhibited tumor growth, with a more pronounced effect when used in combination. Cancers (Basel). 2024 Mar 5;16(5):1050

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.94mL

1.59mL

0.79mL

15.88mL

3.18mL

1.59mL

 

Historical Records

Categories